Top Markets
#1 CyberDEX CyberDEX +372.54%
#2 OVERTAKE OVERTAKE +56.57%
#3 ALEO ALEO +43.43%
#4 Nillion Nillion +34.21%
#5 Clearpool Clearpool +27.85%
#6 Playnance Playnance +23.56%
#7 deBridge deBridge +23.20%
#8 龙虾 (Lobster) 龙虾 (Lobster) +19.17%
#9 AUKI AUKI +18.69%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +16.88%
Coin of the day
CyberDEX CyberDEX
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Intellipharmaceutics International Inc. Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc.

IPCI
Kedudukan dalam Saham #37499
Intellipharmaceutics International Inc., founded in Toronto, Canada, in 1998,... Intellipharmaceutics International Inc., founded in Toronto, Canada, in 1998, is a pharmaceutical company that focuses on the research, development, and manufacturing of innovative and generic controlled-release and targeted-release oral solid dosage medications, primarily for the United States market. The company leverages its patented Hypermatrix technology to create advanced drug delivery systems, an array of product candidates, and a robust pipeline across diverse therapeutic areas, including neurological, cardiovascular, gastrointestinal, diabetes, and pain management conditions. Its current product portfolio includes extended-release formulations like Focalin XR for hyperactivity disorder, Keppra XR for partial onset seizures, Effexor XR to treat depression, and Protonix for gastroesophageal reflux disease. Other offerings feature Glucophage XR for type 2 diabetes, Seroquel XR for schizophrenia and mood disorders, Lamictal XR for epilepsy, Pristiq for depression, Coreg CR for heart failure and hypertension, and Ranexa for chronic angina. Furthermore, Intellipharmaceutics is actively developing additional controlled-release drugs such as OxyContin for pain relief and Regabatin XR for neuropathic pain management. The company operates under a license and commercialization agreement with Par Pharmaceutical Inc.
Harga Saham
$0.05897422
Disegerakkan terakhir: 2024-04-02
Modal Pasaran
$1.64M
Perubahan (1 hari)
0.07%
Perubahan (1 tahun)
-60.68%
Negara
CA
Perdagangan Intellipharmaceutics International Inc. (IPCI)

Kategori

Healthcare
Pendapatan untuk Intellipharmaceutics International Inc. (IPCI)
Pendapatan pada Aug 2023 TTM: $-3.17M
Menurut laporan kewangan terkini Intellipharmaceutics International Inc., pendapatan semasa syarikat ialah $-3.17M. Pada tahun 2021, syarikat memperoleh pendapatan sebanyak $-2.89M, peningkatan berbanding pendapatan pada tahun 2020 yang berjumlah $-5.26M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Intellipharmaceutics International Inc. dari 1999 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
2026 (TTM) $-3.17M 9.75%
2022 $-2.89M 0.00%
2021 $-2.89M -45.11%
2020 $-5.26M 56.62%
2019 $-3.36M -75.57%
2018 $-13.75M 55.21%
2017 $-8.86M -12.68%
2016 $-10.14M 36.40%
2015 $-7.44M 92.83%
2014 $-3.86M -66.45%
2013 $-11.50M 135.54%
2012 $-4.88M 95.22%
2011 $-2.50M -56.34%
2010 $-5.73M -55.76%
2008 $-12.94M -56.95%
2007 $-30.07M -49.08%
2006 $-59.05M -25.61%
2005 $-79.37M 13.77%
2004 $-69.77M 173.92%
2003 $-25.47M 104.32%
2002 $-12.47M 36.27%
2001 $-9.15M 41.00%
2000 $-6.49M 0.00%
1999 0.00 0.00%
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -166,580.77%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B 97,328.60%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B 126,654.91%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -61,664.34%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH